智通财经APP获悉,科伦博泰生物-B(06990)盘中涨近7%,截至发稿,涨5.15%,报322.8港元,成交额1.62亿港元。
消息面上,5月29日,默沙东与第一三共联合宣布,主动撤回其HER3靶向ADC药物Patritumab Deruxtecan (HER3-DXd)用于治疗EGFR突变非小细胞肺癌(NSCLC)的上市申请。分析人士称,科伦博泰有望显著受益。
浦银国际指出,科伦博泰Sac-TMT三期3L EGFRm NSCLC披露的PFSOS获益令人鼓舞,强大的安全性数据进一步提升。跨试验数据比较显示Sac-TMT在 EGFRm NSCLC疗效数据全面好于DatoDXd和HER3-DXd,生存获益明显强于Amivantamab联用及依沃西联用,安全性数据优秀。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.